Related Experiment Video
Updated: Jul 4, 2025
Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
Published on: July 25, 2020
Successful treatment of stage IVB ovarian carcinosarcoma with PARP Inhibitor: A case report
Jessica D St Laurent1, Mary Kathryn Abel1, Joyce Liu2
1Division of Gynecologic Oncology, Department of Obstetrics, Gynecology and Reproductive Biology, Dana-Farber Cancer Institute, Harvard Medical School, Brigham and Women's Hospital, Boston, MA, USA.
Abstract:
•Ovarian carcinosarcoma is a rare ovarian cancer histology that has limited treatment options.•In this study, we present an unusual association between carcinosarcoma and a STIC lesion.•In select patients with carcinosarcoma, PARP inhibition may provide clinical benefit.
Insights
Ovarian carcinosarcomas are rare cancers with few treatments. This study found a link to STIC lesions and suggests PARP inhibitors may help some patients.
Area of Science:
- Gynecologic Oncology
- Pathology
- Medical Therapeutics
Background:
- Ovarian carcinosarcoma is an aggressive malignancy with limited therapeutic strategies.
- The rarity of this tumor type necessitates further investigation into its underlying biology and potential treatment avenues.
Observation:
- An infrequent co-occurrence of ovarian carcinosarcoma and a serous tubal intraepithelial carcinoma (STIC) lesion was identified.
- This association suggests a potential shared or sequential origin pathway.
Findings:
- The study highlights a potential therapeutic role for poly (ADP-ribose) polymerase (PARP) inhibition in managing select cases of ovarian carcinosarcoma.
- Genomic profiling may identify patients likely to respond to PARP inhibitors.
Implications:
- This finding could expand treatment options for patients diagnosed with ovarian carcinosarcoma.
- Further research into PARP inhibition efficacy in this rare cancer is warranted.
